Category: Vaccine

Page 37«..1020..36373839..5060..»

COVID-19 vaccines helped heart failure patients stay out of the hospital and live longer – Cardiovascular Business

May 15, 2024

Heart failure (HF) patients who received a COVID-19 vaccine are significantly less likely to be hospitalized for HF symptoms or die for any reason, according to new data presented at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC).

The analysis included data from more than 651,000 adult Korean residents with HF. The average patient age was 69.5 years old, and 50% were men. Approximately 83% of patients were fully vaccinated against COVID-19, meaning they received two or more doses of an approved vaccine.

The studys authors compared 73,559 vaccinated patients with 73,559 unvaccinated patients, matching them 1:1 according to age, sex, comorbidities and other relevant patient attributes. The median follow-up period was six months.

Overall, COVID-19 vaccination was associated with an 82% lower risk of all-cause mortality, 47% lower risk of hospitalization for HF and 13% lower risk of testing positive for COVID-19. Vaccinated patients also had lower rates of stroke, heart attack, myocarditis/pericarditis and venous thromboembolism during that six-month period.

Read the original post:

COVID-19 vaccines helped heart failure patients stay out of the hospital and live longer - Cardiovascular Business

AstraZeneca to withdraw its COVID-19 vaccine globally as demand dips, rare side effects revealed – Fox Business

May 15, 2024

Fox News medical contributor Dr. Marc Siegel discusses AstraZeneca admitting that its COVID vaccine can cause side effects and shares why it's important to move every 30 minutes.

The pharmaceutical giant AstraZeneca on Tuesday said it is withdrawing its COVID-19 vaccine worldwide citing low demand and a "surplus of available updated vaccines" since the pandemic.

The vaccine calledVaxzevria was one of a number of shots released onto the market by pharmaceutical companies aimed at preventing people from catching COVID-19.

The company said it would proceed to withdraw Vaxzevria's marketing authorizations within Europe. The vaccine was never approved in the U.S. by the FDA.

POLAND ASKS PFIZER TO RENEGOTIATE COVID-19 VACCINE DEAL

AstraZeneca said that more than 3 billion doses of its vaccine were supplied globally and that "over 6.5 million lives were saved in the first year of use alone." (Reuters/Sergio Perez / Reuters Photos)

"As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.

AstraZeneca said that more than 3 billion doses were supplied globally and that "over 6.5 million lives were saved in the first year of use alone."

"Our efforts have been recognized by governments around the world and are widely regarded as being a critical component of ending the global pandemic," the statement said, according to the Guardian. "We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the COVID-19 pandemic."

VACCINE MAKERS SEE STOCK PRICE BOOST ON BIDEN ADMIN COVID SHOT PUSH

The pharmaceutical giant AstraZeneca on Tuesday said it is withdrawing its COVID-19 vaccine worldwide, citing low demand and a "surplus of available updated vaccines" since the pandemic. (iStock)

According to the Telegraph, AstraZeneca admitted for the first time in court documents that its COVID-19 vaccine can cause rare side effects such as blood clots and low blood platelet counts. The admission came via a U.K. class action lawsuit that sought $125 million for almost 50 victims of AstraZeneca vaccine side effects.

TheEuropean Medicines AgencylistedGuillain-Barr syndromeas a very rare side effect ofVaxzevria in 2021 and added a warning in the product information.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The firm's application to withdraw the vaccine was made on March 5 and came into effect on Tuesday, according to the Telegraph, which first reported the development.

Many countries had already stopped supplying the vaccine before Tuesdays announcement. It has not been available for use in Australia since March 2023, though its use was already being phased out from June 2021 due to the widespread availability of newer vaccines, according to the Guardian.

London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.

Reuters contributed to this report.

Originally posted here:

AstraZeneca to withdraw its COVID-19 vaccine globally as demand dips, rare side effects revealed - Fox Business

COVID-19 vaccine can help people with heart failure live longer, reveals study – Medical Dialogues

May 15, 2024

Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research presented today at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC). Heart Failure is a life-threatening syndrome affecting more than 64 million people worldwide.

Patients with heart failure should be vaccinated against COVID-19 to protect their health, said study author Dr. Kyeong-Hyeon Chun of the National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea. In this large study of patients with heart failure, COVID-19 vaccination was associated with a lower likelihood of contracting the infection, being admitted to hospital because of heart failure, or dying from any cause during a six-month period compared with remaining unvaccinated.

Previous studies have shown the safety of COVID-19 vaccination in patients with cardiovascular diseases including heart failure, and that COVID-19 outcomes are worse in patients with heart failure compared to those without heart failure. However, there has been little research on how vaccines work specifically in patients with heart failure. This nationwide, retrospective study examined the prognosis of heart failure patients according to COVID-19 vaccination status.

This study used the Korean National Health Insurance Service database, which covers nearly all residents of the Republic of Korea, to obtain information on vaccinations and clinical outcomes. Participants who received two or more doses of COVID-19 vaccine were defined as "vaccinated", and those who were not vaccinated or had received just one dose were defined as "unvaccinated".

The study included 651,127 patients aged 18 years or older with heart failure. The average age was 69.5 years and 50% were women. Of the total study population, 538,434 (83%) were defined as vaccinated and 112,693 (17%) as unvaccinated. To control for factors that could influence the relationship between vaccination status and outcomes, the researchers performed 1:1 matching of vaccinated and unvaccinated patients according to age, sex, other health conditions (e.g. high blood pressure, diabetes, high cholesterol, etc.), income, and region of residence. This resulted in 73,559 vaccinated patients and 73,559 unvaccinated patients for the comparative analyses.

The median follow-up was six months. Vaccination was associated with an 82% lower risk of all-cause mortality, 47% lower risk of hospitalisation for heart failure, and 13% reduced risk of COVID-19 infection compared with no vaccination. Regarding cardiovascular complications, vaccination was associated with significantly lower risks of stroke, heart attack, myocarditis/pericarditis, and venous thromboembolism compared to no vaccination.

Dr. Chun said: This was the first analysis of COVID-19 vaccine effectiveness in a large population of heart failure patients, and the first to show a clear benefit from vaccination. The study provides strong evidence to support vaccination in patients with heart failure. However, this evidence may not be applicable to all patients with heart failure, and the risks of vaccination should be considered in patients with unstable conditions.

Read more:

COVID-19 vaccine can help people with heart failure live longer, reveals study - Medical Dialogues

COVID Vaccine May Help Heart Failure Patients Live Longer: Study – Medical Daily

May 15, 2024

Taking the COVID-19 vaccination would not only prevent people from contracting the coronavirus infection, but may also help patients with heart failure live longer, a recent study has revealed.

Heart failure occurs when a person's heart fails to pump enough blood for the body either because it does not fill up with adequate blood or it is too weak to pump properly. The condition affects around 6.5 million Americans over the age of 20.

Studies have shown that COVID-19 affects patients with heart failure severely. The latest study discovered that getting vaccinated against COVID-19 can improve the longevity of heart failure patients by 82% compared to those who are unvaccinated.

"Patients with heart failure should be vaccinated against COVID-19 to protect their health. In this large study of patients with heart failure, COVID-19 vaccination was associated with a lower likelihood of contracting the infection, being admitted to hospital because of heart failure, or dying from any cause during a six-month period compared with remaining unvaccinated," said study author Dr. Kyeong-Hyeon Chun in a news release.

The researchers used data from the Korean National Health Insurance Service database that included information on 651,127 patients over 18 who had heart failure. Of the total population included in the study, 83% were vaccinated. Vaccinated population refers to those people who took at least two doses of COVID shots. To make a comparative study, researchers made a 1:1 match of vaccinated and unvaccinated patients, comparing 73,559 vaccinated patients against an equal number of unvaccinated patients.

"Vaccination was associated with an 82% lower risk of all-cause mortality, 47% lower risk of hospitalization for heart failure, and 13% reduced risk of COVID-19 infection9 compared with no vaccination," the news release stated.

The study also noted that getting vaccinated against COVID-19 significantly lowered the risks of cardiovascular conditions such as stroke, heart attack, myocarditis, pericarditis, and venous thromboembolism.

"This was the first analysis of COVID-19 vaccine effectiveness in a large population of heart failure patients, and the first to show a clear benefit from vaccination. The study provides strong evidence to support vaccination in patients with heart failure. However, this evidence may not be applicable to all patients with heart failure, and the risks of vaccination should be considered in patients with unstable conditions," Dr. Chun said.

See original here:

COVID Vaccine May Help Heart Failure Patients Live Longer: Study - Medical Daily

Health Ministry to address AstraZeneca vaccine concerns this week, says deputy minister – TheStarTV.com

May 15, 2024

Request blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation. Generated by cloudfront (CloudFront)Request ID: noywqGY5ubhAJqB1WtSn8LGVTJxJ_1xCbezJRaz7c-0hslvQWC27Lw==

Here is the original post:

Health Ministry to address AstraZeneca vaccine concerns this week, says deputy minister - TheStarTV.com

Measles second dose vaccine uptake and its associated factors among children aged 2435 months in Northwest … – Nature.com

May 15, 2024

Study setting, design and period

A community-based cross-sectional study was conducted in Shebel Berenta district in northwest Ethiopia between January 2022 and February 2022. Shebel Berenta is one of the 22 districts in Northwest Ethiopia, located 372km from Bahir Dar, the capital city of Amhara National Regional State. It is bordered on the south by Dejen District, on the north by Enarj Enawuga, and on the east by the Abay River32. It is located at an elevation of 18002150m above sea level. Approximately 72.3% of the district is desert (kola), with Woyinadega accounting for the rest (

Figure1)33, and the map of the study area of interest, Shebele Berenta was generated. Based on the 2021 population projection, the district has an estimated population of 136,948. Of those, 68,200 are males and 68,748 are females. There are nineteen kebels (15 rural and 4 urban kebeles) in the district. There are 6 health centers, 23 health posts, 1 primary hospital, 4 private clinics, and 3 drug stores that provide community health services34.

Map of the study area (Shebel Berenta district) (generated using GIS software version 10.5; URL: https://arcgis.software.informer.com/10.5/).

The source population was all mothers or caregivers with children aged less than 60months who have been residing in Shebel Berenta for at least six months. Whereas mothers/caretaker with children aged 2435months who lived in selected kebeles of Shebel Berenta district for at least six months and received the first dose of the measles vaccine were the study population. We exclude mothers/caretakers with children aged 2435months who did not receive the first dose of measles vaccination, were ill or unable to respond, and/or residents of less than six months in the study area.

The sample size was calculated using the single population proportion formula by considering the following assumptions of sample size determination in a cross-sectional study: 50% proportion of MCV2 uptake (since there are no previous studies in the study area of interest), a 95% level of confidence interval (CI), and a margin of error of 5%. Then, the sample size of the study was determined using the general formula:

$${text{n}}=frac{{({text{Z}}1-mathrm{alpha }/2)}^{2}*pq}{{(d)}^{2}}=frac{{(3.84)}^{2}*0.5*0.5}{{(0.05)}^{2}}=385$$

where n=minimum required sample size, p=proportion of MCV2 uptake, q=1-p=50%, d=a margin of error (5%), Z1-/2=level of confidence interval, 1.96 (95% CI).

Then, by considering 10% non-response rates, the required final sample size was 424.

There are a total of nineteen kebeles in Shebel Berenta district. Out of the total, eight kebeles were selected using a computer-generated random sampling system. The study participants were mothers who had children aged 2435months in the selected kebeles. Then, the sample size was proportionally allocated to each selected kebele. A sampling frame (a list of mothers who had children aged 2435months) was prepared at the health post, which was obtained from the family folder (community health information system). Finally, the required subjects were chosen by a simple random sampling technique using a list of children aged 2435months.

It is the uptake of the measles second dose vaccine after being vaccinated for measles first dose 35.

The proportion of children aged 2435months who had received the measles second dose of vaccine before the age of 24months35.

Measles second dose vaccine utilization.

Family size, educational status, marital status, religion, age of the mother, residence, occupation, age of the child, sex of the child, number of births, birth order, distance to health facility, place of delivery, antenatal care service, awareness of measles second dose schedule, knowledge on vaccine preventable disease, utilization of other vaccine antigen such as BCG, MCV1, Pentavalent3, OPV3, Pneumococcal vaccine3, MCV1 and vitamin A supplementation.

A structured, pretested face-to-face interviewer-administered questionnaire adapted from different published literature17,25,26,27,28,29,36 and Ethiopia Mini Demographic Health Survey 201922 was used to collect socio-demographic, socioeconomic, and maternal and health facility-related variables, and child vaccination status. Participants were approached and interviewed after explaining the purpose of the study and requesting to participate. Six well-trained public health professionals with previous experience in data collection have participated in the data collection. The data collection process started immediately after preparing the list of children aged 2435months at the health post from the selected kebeles. The vaccination information of the children was obtained by requesting mothers or caregivers to show the vaccination cards to the data collectors and mothers' or caregivers' verbal reports if the vaccination cards were not available.

The data collection tool was prepared in English, translated into the local language (Amharic), and then returned to English to ensure consistency. Supervisors and data collectors have received two-day data collection training. The training mainly focused on data quality, confidentiality, and privacy. Sampling procedures and instruction sheets were prepared and given to data collectors and supervisors. One week before the actual fieldwork, a pretest was conducted on 5% of mothers/caregivers with children aged 2435months from other kebeles that did not participate in the actual study, and amendments were made based on the results of the pretest. The data were checked for completeness and accuracy by investigators and supervisors daily.

The data was cleaned manually, coded, and entered into Epi Data 6.4 and exported to SPSS version 25 software for further analysis. Descriptive statistics such as frequency, mean, median and proportion were used to describe the study population concerning relevant variables. Before the analysis was done, the assumptions of the binary logistic regression model were checked. Then, bivariate analysis was carried out to find candidate variables for multivariate analysis. Those variables with a p-value<0.25 in the bivariate analysis were included in the multivariate analysis to adjust for confounders. An adjusted odd ratio with 95% CIs was estimated to identify factors associated with measles second dose vaccine uptake, and they were declared statistically significant at a p-value<0.05. HosmerLemeshows goodness of fit test model coefficient was found to be insignificant with a large p-value (0.89), which indicates the fitness of the model.

This study involves human subject and all research methods and procedures were performed in accordance with the Declaration of Helsinki and approved by the Debre Markose University Health Science College Institutional Research Ethics Review Committee (IRERC). Further supporting letters were also obtained from the Shebel Berenta district health office. After the purpose and objective of the study had been explained, informed consent was obtained from each subject. Confidentiality of information was maintained, and the collected data was kept in the form of a file in a secure place where no one could access it except the investigators. Mothers/caretakers with unvaccinated or seriously ill children during data collection were advised by data collectors to go to the nearby health post and cluster health center.

All procedures involving human subject were approved by Debre Markose University, Health Science College Institutional Research Ethics Review Committee (IRERC). Verbal consent was obtained from all subjects.

See the rest here:

Measles second dose vaccine uptake and its associated factors among children aged 2435 months in Northwest ... - Nature.com

AstraZenecas Covid vaccine is no more but its remarkable success must not be forgotten – The Guardian

May 13, 2024

Coronavirus

Although dogged by controversy, the firms coronavirus jab saved the lives of millions and helped avert humanitarian crises in nations unable to access costly alternatives

Sat 11 May 2024 10.29 EDT

Last weeks announcement that AstraZeneca would no longer market its Covid vaccine brings an end to one of the centurys most remarkable medical stories. Created within a year of the arrival of the pandemic, the AZ vaccine was cheap, easily stored and transported, and helped stave off humanitarian crises in Asia and Latin America, where many countries could not afford the more expensive mRNA vaccines that were being snapped up by rich western nations. It is estimated that it saved 6.3 million lives in 2021 alone.

Yet from the start the vaccine created by research teams led by Professor Andy Pollard and Professor Sarah Gilbert at the Oxford Vaccine Centre was dogged by controversy. It was linked to blood clots, US observers criticised protocols for its trials, and French president Emmanuel Macron claimed it was quasi-ineffective for people over 65. In fact, the vaccine is particularly effective for the elderly.

In very rare cases, the AZ vaccine can cause blood clots. According to the British Heart Foundation, one study in the BMJ showed that for every 10 million people vaccinated with AstraZeneca there would be a total of 73 extra cases of blood clots. By contrast 10 million Covid cases would trigger thousands of extra blood clot cases.

Many of the anxieties about the vaccine stemmed from national self-interests. However, others derive from the nature of vaccines themselves, and this raises issues that are likely to re-emerge with the arrival of any new pandemic in coming years, scientists have warned.

A vaccine is unlike any other type of medicine because it works by stimulating a persons anti-pathogen defences, arming them in advance of a future infection. However, this preparation goes beyond helping one individual and can aid the general population, a point stressed by Professor Stephen Evans, of the London School of Medicine and Tropical Hygiene.

If I take a preventative drug such as a statin then I am the only one who benefits, said Evans. However, there are people who cannot mount responses to a vaccine because they are ill or have a weakened immune system. They remain vulnerable. However, if you can build up herd immunity by ensuring the maximum number of people are inoculated, virus levels will drop and the vulnerable will be protected. If we believe we have responsibilities to help others, being vaccinated achieves that. There are moral concerns about being inoculated, in other words.

Convincing the public which has witnessed a rise in anti-vax propaganda in recent years of this may not be easy. In addition, there is a second crucial difference between standard medical treatments and vaccines, added Professor Sir David Spiegelhalter, of the University of Cambridge. We never know the identities of those who benefit [from a vaccine] they are statistical people while those who are harmed can be named and their stories told.

AstraZenecas Covid vaccine provides an example. We only know those who were harmed by it but cannot pinpoint those who benefited. Again, this makes it trickier to pinpoint a vaccines success and assure people of its efficacy. To a certain extent, you can get round this and assess the impact of Covid vaccines by looking at the deaths of frontline workers in the health service during the pandemics early days, added Evans. Hundreds died, but if we had had a vaccine then it is now clear most would probably have survived.

Most virologists and vaccine experts agree: when you look at the AstraZeneca vaccine from a global perspective, it probably benefited tens of millions of people, preventing deaths and reducing long-term consequences of Covid. It was a remarkable success, yet its passing has been marked by many who stressed its side-effects but never touched on its achievements.

The paradox of vaccines is that people forget how important they are, said Professor Adam Finn, of Bristol University. They are like democracy. You enjoy it for a while and then forget how important it is to preserve it. Its a problem.

On the other hand, it is also clear politicians and officials will have to be careful about the claims they make, added Fiona Fox, head of the Science Media Centre. Public trust in vaccines will come from open and honest communication. The benefits massively outweigh the risks as they did with this vaccine.

But you wont win any arguments by claiming that vaccines are 100% safe or running for the hills at the first reports of problems, which unfortunately too many government and NHS communications officers tend to do.

Downplaying risks is always tempting when you need people to take a mostly safe vaccine but its ultimately self-defeating because it erodes trust in the longer term.

Robin McKie and science and environment editor for the Observer

{{topLeft}}

{{bottomLeft}}

{{topRight}}

{{bottomRight}}

{{.}}

One-timeMonthlyAnnual

Other

View original post here:

AstraZenecas Covid vaccine is no more but its remarkable success must not be forgotten - The Guardian

Heart failure patients may live longer with COVID-19 vaccination – Earth.com

May 13, 2024

Heart failure, a life-threatening condition affecting over 64 million people globally, is a heavy burden to bear. But amidst the bleakness, a beacon of hope emerges from surprising quarters: the COVID-19 vaccine.

New research unveiled at the Heart Failure 2024 congress in Lisbon suggests this vaccine could drastically improve the odds for heart failure patients, reducing their risk of death by a staggering 82 percent.

Patients with heart failure should be vaccinated against COVID-19 to protect their health, noted Dr. Kyeong-Hyeon Chun, the studys lead author. This isnt mere speculation. The research, a comprehensive analysis of over 650,000 Korean heart failure patients, reveals a stark contrast between those vaccinated and those not.

The vaccinated group experienced a much lower risk of not only death but also hospitalization due to heart failure and even contracting COVID-19 in the first place. This revelation is groundbreaking, given that previous research had primarily focused on the vaccines safety in heart failure patients, not its potential to extend their lives.

This study was remarkable for its sheer size and comprehensive approach. It drew upon the Korean National Health Insurance Service database, a vast repository of health information that encompasses a significant majority of the Korean population. This allowed researchers to access an enormous sample size, ensuring the studys findings were statistically robust and generalizable.

To further enhance the validity of their results, researchers carefully matched vaccinated and unvaccinated patients based on a variety of factors, including age, sex, socioeconomic status, and pre-existing health conditions. This meticulous matching process ensured that the two groups were as similar as possible, eliminating potential confounding variables and isolating the effects of vaccination.

The outcomes of this rigorous study were undeniable. After six months, the data revealed that vaccination led to a substantial reduction in the risk of death from any cause, hospitalization due to heart failure, and COVID-19 infection itself. Furthermore, the vaccinated group exhibited a significantly lower risk of experiencing severe cardiovascular events such as stroke, heart attack, and blood clots.

This is more than just a statistic. Its a potential turning point in how we approach heart failure. While the COVID-19 vaccines primary role has been to protect against the virus, this study suggests it could be a powerful weapon in the fight against heart failure itself.

This was the first analysis of COVID-19 vaccine effectiveness in a large population of heart failure patients, and the first to show a clear benefit from vaccination, Dr. Chun emphasized. This study isnt just about numbers; its about real lives saved, hospitalizations prevented, and the potential for a brighter future for millions battling heart failure.

While the studys findings are undoubtedly a significant step forward in understanding the potential benefits of COVID-19 vaccination for heart failure patients, its crucial to approach these results with a nuanced perspective.

The study population, while extensive, was primarily based in Korea, and the specific demographics and healthcare practices of that region might not perfectly translate to other populations worldwide. Additionally, the studys median follow-up period of six months, while substantial, doesnt capture the long-term effects and potential complications of vaccination for heart failure patients.

Furthermore, heart failure is a complex and heterogenous condition with varying degrees of severity and underlying causes. While the study accounted for numerous factors, such as age and co-morbidities, it might not have captured the full spectrum of individual differences that could influence the vaccines effectiveness and safety. For instance, patients with specific genetic predispositions, allergies, or those undergoing particular treatments might experience different responses to the vaccine.

Therefore, its imperative for individuals diagnosed with heart failure to view this study as a starting point for a more personalized conversation with their healthcare provider. This dialogue should involve a detailed examination of the patients medical history, current health status, and individual risk factors.

Its only through such a comprehensive and individualized approach that the potential benefits and risks of COVID-19 vaccination can be accurately assessed and tailored to each patients unique circumstances.

The COVID-19 vaccine, initially hailed as a shield against a deadly virus, may now be a lifeline for those grappling with heart failure. Its not just about fighting the virus; its about bolstering the heart, reducing complications, and ultimately, increasing the odds of survival.

If you or someone you know is living with heart failure, this research is a call to action. Talk to your doctor about the potential benefits of the COVID-19 vaccine. It could be a simple step towards a longer, healthier life.

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

Go here to see the original:

Heart failure patients may live longer with COVID-19 vaccination - Earth.com

Heart failure patients who have taken Covid vaccine likely to live longer: Study – The Sentinel Assam

May 13, 2024

New Delhi: Patients with heart failure who are vaccinated against Covid-19 are 82 per cent more likely to live longer than those who are not vaccinated, a new study said on Saturday. The study presented at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC), used the Korean National Health Insurance Service database to obtain information on vaccinations and clinical outcomes.

Participants who received two or more doses of the Covid-19 vaccine were described as "vaccinated", and those who were not vaccinated or had received just one dose were defined as "unvaccinated".

Heart Failure is a life-threatening syndrome affecting more than 64 million people globally.

In this large study of patients with heart failure, Covid-19 vaccination was associated with a lower likelihood of contracting the infection, being admitted to hospital because of heart failure, or dying from any cause during a six-month period compared with remaining unvaccinated, said study author Dr Kyeong-Hyeon Chun of the National Health Insurance Service Ilsan Hospital, Republic of Korea.

The study comprised 651,127 heart failure patients over the age of 18. The average age was 69.5 years, and 50 per cent were female. Of the whole study population, 538,434 (83 per cent) were classified as vaccinated, and 112,693 (17 per cent) as unvaccinated.

The researchers found that vaccination was associated with an 82 per cent lower risk of all-cause mortality, 47 per cent lower risk of hospitalisation for heart failure, and 13 per cent reduced risk of Covid-19 infection compared with no vaccination.

Regarding cardiovascular complications, vaccination was associated with significantly lower risks of stroke, heart attack, myocarditis/pericarditis, and venous thromboembolism compared to no vaccination, the researchers mentioned.

"The study provides strong evidence to support vaccination in patients with heart failure. However, this evidence may not be applicable to all patients with heart failure, and the risks of vaccination should be considered in patients with unstable conditions," Chun said.

Also Read: Doctors warn gym goers as sudden heart attacks return, killing at least 4 in 24 hrs (sentinelassam.com)

Go here to see the original:

Heart failure patients who have taken Covid vaccine likely to live longer: Study - The Sentinel Assam

Heart failure patients improve with COVID vaccinations – Cosmos

May 13, 2024

A big Korean analysis of people with heart failure has revealed substantial positive impacts of getting vaccinated against COVID-19.

The study was drawn from the Korean National Health Insurance Service database, which covers nearly all residents of the country.

It contained 651,127 patients aged 18 years or older with heart failure.

The study found heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated; a 47% lower risk of hospitalisation for heart failure and 13% reduced risk of COVID-19 infection, compared with people who were not vaccinated.

The research was presented at Heart Failure 2024, a scientific congress of the European Society of Cardiology, in Lisbon, Portugal.

Heart failure is a life-threatening syndrome affecting more than 64 million people worldwide.

Patients with heart failure should be vaccinated against COVID-19 to protect their health, says study author Dr. Kyeong-Hyeon Chun of the Ilsan Hospital, Goyang, in the Republic of Korea. In this large study of patients with heart failure, COVID-19 vaccination was associated with a lower likelihood of contracting the infection, being admitted to hospital because of heart failure, or dying from any cause during a six-month period compared with remaining unvaccinated.

Previous studies have shown that COVID-19 outcomes are worse in patients with heart failure compared to those without heart failure.

Participants who received two or more doses of COVID-19 vaccine were defined as vaccinated, and those who were not vaccinated or had received just one dose were defined as unvaccinated.

The average age of people drawn from the data was 69.5 years and 50% were women. Of the total study population, 538,434 (83%) were defined as vaccinated and 112,693 (17%) as unvaccinated.

The researchers performed 1:1 matching of vaccinated and unvaccinated patients according to age, sex, other health conditions (e.g. high blood pressure, diabetes, high cholesterol, etc.), income, and region of residence. This resulted in 73,559 vaccinated patients and 73,559 unvaccinated patients for the comparative analyses.

In addition to lower mortality rates, vaccination was associated with significantly lower risks of stroke, heart attack, myocarditis/pericarditis, and venous thromboembolism compared to people who were not vaccinated.

Chun says this is believed to be the first analysis of COVID-19 vaccine effectiveness in a large population of heart failure patients, and the first to show a clear benefit from vaccination for that cohort.

The study provides strong evidence to support vaccination in patients with heart failure. However, this evidence may not be applicable to all patients with heart failure, and the risks of vaccination should be considered in patients with unstable conditions, Chun says.

Go here to see the original:

Heart failure patients improve with COVID vaccinations - Cosmos

Page 37«..1020..36373839..5060..»